Literature DB >> 26615585

Response to low dose indomethacin in two children with nephrogenic diabetes insipidus.

Devi Dayal1, Savita Verma Attri2, Anil Kumar Bhalla3, Rakesh Kumar4.   

Abstract

Two children with nephrogenic diabetes insipidus (NDI) were treated with oral indomethacin (0.75-1.2 mg/kg/day) three times a day for a mean duration of 3 yrs. Remission occurred in both patients in terms of achieving a normal fluid balance and body growth and the drug was withdrawn in one patient after 2 yrs. The treatment was well tolerated and no side effects were noted. The mean duration of follow-up was 6.5 yrs. These long-term observations of a favourable response to low dose indomethacin in 2 children with NDI need to be tested on larger number of patients. © Polish Society for Pediatric Endocrinology and Diabetology.

Entities:  

Keywords:  children; cyclooxygenase inhibitors; indomethacin; nephrogenic diabetes insipidus

Mesh:

Substances:

Year:  2015        PMID: 26615585     DOI: 10.18544/PEDM-20.04.0018

Source DB:  PubMed          Journal:  Pediatr Endocrinol Diabetes Metab        ISSN: 2083-8441


  3 in total

Review 1.  Hereditary Nephrogenic Diabetes Insipidus: Pathophysiology and Possible Treatment. An Update.

Authors:  Serena Milano; Monica Carmosino; Andrea Gerbino; Maria Svelto; Giuseppe Procino
Journal:  Int J Mol Sci       Date:  2017-11-10       Impact factor: 5.923

2.  Case Report: A Case of Congenital Nephrogenic Diabetes Insipidus Caused by Thr273Met Mutation in Arginine Vasopressin Receptor 2.

Authors:  Li Huang; Lina Ma; Linjing Li; Jiajia Luo; Tianhong Sun
Journal:  Front Pediatr       Date:  2021-07-15       Impact factor: 3.418

3.  A Novel Mutation in the AVPR2 Gene Causing Congenital Nephrogenic Diabetes Insipidus

Authors:  Aslı Çelebi Tayfur; Tuğçe Karaduman; Merve Özcan Türkmen; Dilara Şahin; Aysun Çaltık Yılmaz; Bahar Büyükkaragöz; Ayşe Derya Buluş; Hatice Mergen
Journal:  J Clin Res Pediatr Endocrinol       Date:  2018-07-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.